Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service.
Yadagiri, Mahi Burbridge, Wyn Irwin, Susan P Gandhi, Hardeep Bashir, Tahira Allden, Rachael A Wyres, Melanie Cull, Melissa Bleasdale, John P
Yadagiri, Mahi
Burbridge, Wyn
Irwin, Susan P
Gandhi, Hardeep
Bashir, Tahira
Allden, Rachael A
Wyres, Melanie
Cull, Melissa
Bleasdale, John P
Citations
Altmetric:
Affiliation
Guy's and St Thomas' Hospitals; Sandwell and West Birmingham NHS Trust
Other Contributors
Publication date
2022-03-29
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
There is a worldwide pandemic of type 2 diabetes (T2D) and obesity.1 In clinical practice, many patients fail to achieve adequate glycaemic control despite lifestyle advice and maximal doses of oral and injectable medications.2 The evidence suggests that Roux-en-Y gastric bypass (RYGB) is more effective than intensive anti-diabetes medical ther apy, and this has led to a recent joint statement by interna tional diabetes organizations recommending increased use of metabolic surgery in the treatment of T2D with obesity.
Citation
Ryder, R. E. J., Yadagiri, M., Burbridge, W., Irwin, S. P., Gandhi, H., Bashir, T., Allden, R. A., Wyres, M., Cull, M., Bleasdale, J. P., Fogden, E. N., Anderson, M. R., & Sen Gupta, P. (2022). Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service. Diabetic medicine : a journal of the British Diabetic Association, 39(7), e14827. https://doi.org/10.1111/dme.14827
Type
Article